ERBB2 and neoplasm: In the trial, twenty-one days after intracranial inoculation, HER2-positive SKOV3-Luc-IP1 and HER2-positive MDA-MB-231Br tumor-bearing mice were injected intravenously with 111In-DTPA*-2Rs15d or 111In-DTPA*-trastuzumab.